April 11, 2022 | Bio-ITWorld today announced the 2022 Innovative Practices Awards winners. Four grand prize awards were granted to AstraZeneca, Guardant Health with IQVIA, Merck KGaA, Darmstadt, Germany, with Genedata, and Quantum Leap Healthcare Collaborative / University of California San Francisco with OpenClinica. The awards ceremony will be held during the plenary program on Tuesday, May 3, at the 2022 Bio-IT World Conference & Expo in Boston.
Since 2003, Bio-IT World has hosted an elite awards program with the goal of highlighting outstanding examples of how technology innovations and strategic initiatives can be applied to advance life sciences research. This year’s winners represent excellence in innovation in the categories of Clinical & Health-IT, IT Infrastructure, Knowledge Management, and Personalized & Translational Medicine.
“The Bio-IT World community consistently delivers innovation to drive the life sciences forward,” said Allison Proffitt, Bio-IT World Editorial Director. “This year, our panel of peer judges were particularly impressed with efforts to shift processes and data culture to empower data science and AI, with comprehensive and integrated tools for drug discovery, and with forward-thinking approaches to structuring and normalizing both clinical and real-world data.
Quantum Leap Healthcare Collaborative nominated by OpenClinica
A major expense in clinical trials is the collection and abstraction of clinical data. This expense is further compounded by human errors that require additional investments in data cleaning/validation. Enhancements in the efficiency and accuracy of data capture are important advances in controlling the rising costs of clinical trials. We have established a flexible framework for integration and completion of Electronic Case Report Forms(eCRFs) through automated, direct capture from Electronic Health Record (EHR)systems. OneSource, launched within a participant’s EHR patient chart, automatically populates structured eCRFs by extracting data directly from the EHR, without need of manual abstraction. Deployed at eight clinical sites in the multicenter, adaptive phase 2 I-SPY-COVID-19 platform trial, we demonstrate a time savings of 61% over sites using manual data abstraction. Furthermore, at sites using OneSource, data errors were eliminated, leading to additional downstream cost savings in cleaning/validation costs. OneSource has the additional benefits of low implementation costs and reusability across sites.
Learn more about this project during the team’s presentation in the Digitization of Clinical Development and Clinical Trials track on Thursday, May 5, 2022 12:25-12:55pm.